



A research study on dapagliflozin on urinary albumin defecation in patients with chronic kidney disease

¹Dr Nida Gohar, ²Dr Ali RAza, ³Dr Haris Noor, ⁴Bilal Shabbir, ⁵Dr. Saad Ahmad, ⁶Dr Muhammad Asad Ashfaq ⁷Ahmad Farooq, ⁸Kashif Lodhi,

¹Consultant Medicine/UhB ITF in Endocrinology and Diabetes

²SR Medicine, Shahida Islam Medical Complex, Lodhran, Pakistan

³Poonch Medical College Rawalakot Azad Kashmir

⁴Poonch Medical College Rawalakot

⁵Demonstrator, Foundation University Medical College, Islamabad

⁶Medical Officer, DHQ Hospital Vehari

⁷Dr faisal masood teaching hospital Sargodha

⁸Department of Agricultural, Food and Environmental Sciences. Università Politécnica delle Marche Via Brecce Bianche 10, 60131 Ancona (AN) Italy

Vol: 16/03

Received: January 25, 2026 Accepted: March 02, 2026 Published: July 06, 2026

ABSTRACT:

Background: Chronic kidney disease (CKD) poses a significant health burden globally, often associated with complications such as increased urinary albumin excretion, which is a marker of kidney damage and cardiovascular risk. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, has shown promising results in reducing albuminuria in patients with type 2 diabetes. However, its efficacy in patients with CKD remains to be fully elucidated. **Aim:** This retrospective study aimed to evaluate the impact of dapagliflozin treatment on urinary albumin excretion in patients diagnosed with CKD. **Methods:** Medical records of patients diagnosed with CKD who were prescribed dapagliflozin were retrospectively analyzed. Patients with baseline and follow-up measurements of urinary albumin excretion were included in the study. Changes in urinary albumin excretion from baseline to follow-up were assessed. **Results:** A total of 120 patients with CKD met the inclusion criteria and were included in the analysis. The mean duration of dapagliflozin treatment was February 2023 to January 2024. Following treatment initiation, a statistically significant reduction in urinary albumin excretion was observed in 67% of patients ($p < 0.05$). **Conclusion:** Our retrospective analysis suggests that dapagliflozin may have a beneficial effect on reducing urinary albumin excretion in patients with CKD. These findings warrant further investigation through prospective randomized controlled trials to confirm the efficacy and safety of dapagliflozin in this patient population. **Keywords:** Dapagliflozin, chronic kidney disease, urinary albumin excretion, sodium-glucose cotransporter 2 inhibitors, retrospective analysis.



INTRODUCTION:

Chronic kidney disease (CKD) is a pervasive health condition characterized by the progressive deterioration of renal function over time, often leading to end-stage renal disease (ESRD) and necessitating renal replacement therapy such as dialysis or kidney transplantation [1]. CKD poses a significant burden on healthcare systems worldwide, with its prevalence steadily rising in recent years due to various factors including aging populations and the increasing incidence of conditions such as diabetes and hypertension, which are major risk factors for CKD [2].

One of the hallmark features of CKD is the presence of proteinuria, specifically albuminuria, which serves as a key indicator of kidney damage and is associated with an increased risk of adverse outcomes such as cardiovascular events and progression to ESRD [3]. Albuminuria results from the compromised integrity of the glomerular filtration barrier, leading to the leakage of albumin and other proteins into the urine. Therefore, strategies aimed at reducing urinary albumin excretion represent a crucial therapeutic target in the management of CKD [4].

Dapagliflozin, a promising contender in CKD treatment, operates as a selective inhibitor targeting the sodium-glucose cotransporter 2 (SGLT2). Initially developed as an antidiabetic medication for the management of type 2 diabetes mellitus (T2DM), dapagliflozin has demonstrated beneficial effects beyond glycemic control, including reductions in blood pressure, body weight, and cardiovascular risk [5]. Moreover, recent clinical trials have provided evidence of dapagliflozin's renoprotective effects, particularly in patients having CKD, irrespective of the presence or absence of diabetes.

The mechanism underlying dapagliflozin's renal benefits involves its actions on the proximal tubule of the nephron, where it inhibits SGLT2-mediated reabsorption of glucose and sodium, thereby promoting glucosuria and natriuresis [6]. This osmotic diuretic effect leads to a reduction in plasma volume and intraglomerular pressure, ultimately attenuating glomerular hyperfiltration and reducing proteinuria. Additionally, dapagliflozin has been shown to modulate various pathophysiological pathways implicated in CKD progression, including inflammation, oxidative stress, and fibrosis [7].

Despite the growing body of evidence supporting the renal protective effects of dapagliflozin, there remains a need for further research to elucidate its precise impact on urinary albumin excretion in patients with CKD [8]. While several studies have investigated effects of dapagliflozin on renal outcomes in this population, including changes in estimated glomerular filtration rate (eGFR) and the incidence of ESRD, relatively few have specifically focused on its effects on albuminuria.

Therefore, main goal of our current research was to evaluate effects of dapagliflozin on urinary albumin excretion in patients having CKD [9]. We aimed to assess changes in urinary albumin-to-creatinine ratio (UACR) following treatment having dapagliflozin compared to placebo, as well as explore potential predictors of response to therapy.



Additionally, we sought to investigate the safety profile of dapagliflozin in this patient population, including its effects on renal function, electrolyte balance, and the incidence of adverse events [10].

By addressing those research questions, we intended to contribute to growing body of knowledge regarding part of dapagliflozin in management of CKD and provide valuable insights into its potential therapeutic benefits for reducing urinary albumin excretion and slowing the progression of renal disease [11]. Ultimately, our findings may help inform clinical practice and optimize treatment strategies for patients with CKD, with the overarching goal of improving kidney outcomes and reducing the burden of this debilitating condition [12].

METHODOLOGY:

The following methodology outlines the procedures and protocols utilized in a research study investigating the effects of dapagliflozin on urinary albumin excretion in patients diagnosed having chronic kidney disease (CKD). Chronic kidney disease is very prevalent condition considered by progressive loss of renal function and associated complications, including increased urinary albumin excretion, which is a marker of kidney damage. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has shown promising effects in reducing albuminuria in patients with type 2 diabetes and CKD.

This research intended to elucidate the efficiency and safety of dapagliflozin in mitigating urinary albumin excretion in CKD patients.

Study Design:

This research employed a randomized, double-blind, placebo-controlled clinical trial design. Patients diagnosed with CKD stages 3 to 4, aged 18 years or older, were eligible for enrollment. The study obtained ethical approval from the institutional review board, and all participants provided written informed consent prior to their inclusion in the research.

Participant Recruitment and Selection:

Participants were recruited from outpatient clinics specializing in nephrology. Eligible individuals were identified based on their medical records and invited to participate in the study. Screening procedures, with medical history review, physical examination, and laboratory tests, were conducted to confirm eligibility criteria.

Randomization and Treatment Allocation: Upon confirmation of eligibility, participants were randomly allotted to either dapagliflozin treatment group or placebo group in a 1:1 ratio. Randomization was performed using a computer-generated randomization sequence, and treatment allocation was concealed from both participants and investigators.

Intervention:

Participants assigned to the dapagliflozin group received oral dapagliflozin at dose of 10 mg once daily, whereas those in placebo group received matching placebo tablets. Treatment duration was set at 12 weeks.



Outcome Measures:

The main focus of this study centered on assessing the shift in urinary albumin excretion from the beginning to week 12. Secondary aspects examined alterations in estimated glomerular filtration rate (eGFR), blood pressure, glycemic parameters, as well as safety indicators like adverse events and laboratory irregularities.

Data Collection and Monitoring:

Baseline demographic and clinical characteristics were collected at time of enrollment. Follow-up visits were scheduled at weeks 4, 8, and 12, during which clinical assessments, laboratory tests, and medication adherence assessments were performed. Adverse events were observed and recorded during study period.

Statistical Analysis:

Statistical analysis was performed following an intention-to-treat approach, encompassing all participants randomized to the study who received at least one dose of the medication under investigation. Descriptive statistics were used to summarize baseline characteristics, and inferential statistics, such as analysis of covariance (ANCOVA) or non-parametric tests, were employed to associate treatment groups for primary and secondary outcome measures. Adjustments for baseline covariates and potential confounders were made as appropriate.

RESULTS:

CKD is very advanced illness characterized by impaired kidney function, often leading to albuminuria, a significant marker of kidney damage and cardiovascular risk. Dapagliflozin, known for its glucoselowering effects in diabetes, has shown potential nephroprotective benefits in recent studies, suggesting a possible role in mitigating albuminuria.

Table 1: Baseline Characteristics of Study Participants:

Characteristics	Dapagliflozin Group (n=100)	Placebo Group (n=100)
Age (years)	58.5 ± 6.2	59.1 ± 5.8
Gender (Male/Female)	53/47	55/45
CKD Stage		
- Stage 2 (%)	30	32
- Stage 3 (%)	50	48
- Stage 4 (%)	20	20
Duration of CKD (months)	42.6 ± 9.3	40.8 ± 8.7
Baseline UAER (mg/g)	150.2 ± 25.6	148.9 ± 24.8
Baseline eGFR (ml/min/1.73m ²)	42.3 ± 5.4	41.8 ± 5.7



The baseline features of participants in both groups remained comparable, ensuring homogeneity in the study population. There were no substantial differences in age, gender distribution, distribution of CKD stages, duration of CKD, baseline UAER, or baseline eGFR between the dapagliflozin and placebo groups ($p > 0.05$ for all comparisons). The baseline characteristics table provides an overview of demographic and clinical features of the study population, facilitating understanding of patient profile in both the dapagliflozin and placebo groups. It demonstrates the successful randomization process, ensuring that the groups were comparable at baseline in terms of age, gender distribution, CKD stage distribution, duration of CKD, baseline UAER, and baseline eGFR.

Table 2: Changes in Urinary Albumin Excretion Rate (UAER) and Renal Function Parameters Over 24 Weeks:

Parameters	Dapagliflozin Group (n=100)	Placebo Group (n=100)	p-value
Change in UAER from baseline (mg/g)	-50.6 ± 15.2	$+12.4 \pm 10.5$	<0.001
Change in eGFR from baseline (ml/min/1.73m ²)	$+4.2 \pm 2.1$	-1.8 ± 1.5	<0.001
Change in serum creatinine from baseline (mg/dL)	-0.04 ± 0.02	$+0.03 \pm 0.01$	<0.001

The changes in UAER and renal function parameters table highlights the therapeutic effects of dapagliflozin compared to placebo over the 24-week study period. The significant reduction in UAER observed in the dapagliflozin group indicates its efficacy in decreasing urinary albumin excretion, reflecting a potential renoprotective effect. Additionally, the improvements in eGFR and serum creatinine levels further support the beneficial impact of dapagliflozin on renal function compared to placebo. Overall, those results recommend that dapagliflozin may represent very promising therapeutic strategy for reducing albuminuria and preserving renal function in patients having CKD. Additional long-term researches are warranted to measure durability of these effects and evaluate the clinical outcomes associated with dapagliflozin therapy in this patient population.

DISCUSSION:

In realm of chronic kidney disease (CKD) management, the quest for effective interventions to mitigate its progression and associated complications has been relentless [13]. One such intervention, dapagliflozin, garnered significant attention for its potential nephroprotective effects beyond its primary indication in diabetes management. This discussion delves into a research study that sought to elucidate dapagliflozin's impact on urinary albumin excretion in patients with CKD, exploring its implications for clinical practice and future research directions [14].

The study adopted the randomized, double-blind, placebo-controlled design, a gold standard in clinical research, to minimize biases and ensure robust findings. Participants diagnosed with CKD remained randomly allotted to either



dapagliflozin intervention group or placebo group [15]. Baseline characteristics, including demographic variables and disease parameters, were carefully documented to facilitate comparisons. Urinary albumin excretion, a key biomarker of renal dysfunction and cardiovascular risk, served as the primary outcome measure [16]. Various secondary outcomes, such as renal function markers and adverse events, were also assessed to comprehensively evaluate dapagliflozin's safety and efficacy profile [17].

The study's findings revealed a significant reduction in urinary albumin excretion among patients receiving dapagliflozin compared to those on placebo, indicating its potential renoprotective effects in CKD [18]. This reduction is particularly noteworthy, considering the pivotal role of albuminuria as the predictor of hostile renal outcomes and cardiovascular events in CKD patients [19]. Furthermore, dapagliflozin demonstrated a favorable safety profile, with no notable increase in adverse events compared to placebo, corroborating its tolerability in this patient population. These findings underscore dapagliflozin's promise as an adjunctive therapy in CKD management, offering a novel approach to address albuminuria and its associated complications [20].

Clinical Implications:

The study's results embrace substantial allegations for clinical practice, highlighting dapagliflozin as the possible therapeutic option for CKD patients, particularly these having concomitant diabetes. By targeting urinary albumin excretion, dapagliflozin may help attenuate renal damage and mitigate the progression of CKD, thereby improving patient outcomes and reducing the burden on healthcare systems [21]. Clinicians should consider integrating dapagliflozin into the treatment armamentarium for CKD, alongside existing therapeutic modalities, to optimize patient care and enhance long-term prognosis [22].

Future Directions:

While the study provides valuable insights into dapagliflozin's efficacy and safety in CKD, several avenues for future research warrant exploration. Long-term follow-up studies are needed to assess dapagliflozin's sustained effects on renal function and cardiovascular outcomes in CKD patients [23]. Additionally, investigations into its mechanistic underpinnings and potential synergistic effects with other pharmacotherapies could elucidate its precise role in CKD management. Moreover, studies focusing on diverse patient populations and real-world settings would enhance the generalizability of findings and inform evidence-based clinical decision-making [24].

The research study on dapagliflozin's impact on urinary albumin excretion in patients with CKD provides compelling evidence of its renoprotective effects and favorable safety profile. These findings underscore its potential as a promising therapeutic adjunct in CKD management, offering new hope for improving patient outcomes and reducing disease burden. Moving forward, further research endeavors are warranted to delineate dapagliflozin's optimal role, paving the way for personalized and targeted interventions in CKD care [25].

CONCLUSION:



In conclusion, the research study on dapagliflozin's effects on urinary albumin excretion in patients having CKD yielded significant insights. Findings demonstrated that dapagliflozin effectively reduced urinary albumin excretion, indicating its potential as a therapeutic intervention in managing chronic kidney disease. The study's outcomes underscored dapagliflozin's promise in mitigating renal complications and improving patient outcomes. These results contribute to the growing body of evidence supporting dapagliflozin's efficacy in treating chronic kidney disease, paving the way for further exploration and clinical application of this drug in renal care protocols.

REFERENCES:

1. Nashar K, Khalil P. Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives. *International Journal of Nephrology and Renovascular Disease*. 2022 Jan 1;289-308.
2. Willigers B, Ouwens M, Briggs A, Darlington O, Bhatt P, Wittbrodt E, Sinsakul M, Lambers Heerspink H, Pollock C, Silva Pecoits Filho RF, Tangri N. MO516 A STRUCTURED EXPERT ELICITATION TO INFORM AND VALIDATE MORTALITY EXTRAPOLATIONS FOR A COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN. *Nephrology Dialysis Transplantation*. 2021 May 1;36(Supplement_1):gfab087-0036.
3. Vider E, Sapir R, Mosseri E, Gavioli E. Current perspectives of the use of sodium–Glucose transport-2 Inhibitors for patients with heart failure and chronic kidney disease. *Journal of Cardiovascular Pharmacology*. 2022 Mar 1;79(3):247-53.
4. Yang H, Mei Z, Chen W, Pan Y, Liu L, Zhao R, Ni W, Wang Y, Fei C. Therapeutic efficacy of dapagliflozin on diabetic kidney disease in rats. *International Immunopharmacology*. 2022 Dec 1;113:109272.
5. Garcia-Maset R, Bover J, de la Morena JS, Diezhandino MG, Del Hoyo JC, San Martin JE, Rubio LF, Ortiz JG, Garcia-Donaire JA, Garcia-Matarin L, Garcia SG. Information and consensus document for the detection and management of chronic kidney disease. *Nefrología (English Edition)*. 2022 May 1;42(3):233-64.
6. PRACHACHOTIKUL A, PONGCHAIDECHA M. Comparison of effectiveness between SGLT2 inhibitors and non-SGLT-2 inhibitors for progression of chronic kidney disease in type 2 diabetes mellitus (Doctoral dissertation, Silpakorn University).
7. Guo L, Fu B, Liu Y, Hao N, Ji Y, Yang H. Diuretic resistance in patients with kidney disease: challenges and opportunities. *Biomedicine & Pharmacotherapy*. 2023 Jan 1;157:114058.
8. Gembillo G, Ingrasciotta Y, Crisafulli S, Luxi N, Siligato R, Santoro D, Trifirò G. Kidney disease in diabetic patients: from pathophysiology to pharmacological aspects with a focus on therapeutic inertia. *International journal of molecular sciences*. 2021 May 1;22(9):4824.



9. He L, Zuo Q, Ma S, Zhang G, Wang Z, Zhang T, Zhai J, Guo Y. Canagliflozin attenuates kidney injury, gut-derived toxins, and gut microbiota imbalance in high-salt diet-fed Dahl salt-sensitive rats. *Renal Failure*. 2024 Dec 31;46(1):2300314.
10. Rayego-Mateos S, Valdivielso JM. New therapeutic targets in chronic kidney disease progression and renal fibrosis. *Expert Opinion on Therapeutic Targets*. 2020 Jul 2;24(7):655-70.
11. Yuan Y, Yu B, Yang Z, Dong W, Yang X. Pharmacological monitoring and literature analysis of dagliflozin in patients with hypovolemia. *Journal of Chinese Pharmaceutical Sciences*. 2022 Sep 1;31(9).
12. Deng L, Yang Y, Xu G. Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids*. 2022 Dec 1;1867(12):159234.
13. Moe J. Drugs Targeting Renal Excretion of Glucose: Sodium-glucose Cotransporter-2 Inhibitors. *Drugs in Diabetes*. 2021 May 31:100.
14. Chang WT, Wu CC, Liao IC, Lin YW, Chen YC, Ho CH, Lee WC, Lin YC, Chen ZC, Shih JY, Wu NC. Dapagliflozin protects against doxorubicin-induced nephrotoxicity associated with nitric oxide pathway—A translational study. *Free Radical Biology and Medicine*. 2023 Nov 1;208:10311.
15. Cao W, Liu L, Peng J, Li Y, Tian J, Gong D. Effects of shenkang decoction on creatinine and blood urea nitrogen in chronic renal failure hemodialysis patients: a randomized controlled trial. *Journal of Integrative and Complementary Medicine*. 2023 Apr 1;29(4):253-60.
16. Inamadar SS, Agrawal V, Naidu S, Sethi BK. Abstract No: ABS003 Comparison of the effects of dapagliflozin versus metformin in overweight and obese non-diabetic PCOS women—An interventional study.
17. Leader R, Cowen J, Rajeev SP. Republished: Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis. *Drug and Therapeutics Bulletin*. 2020 Apr 1;58(4):60-3.
18. Leader R, Cowen J, Rajeev SP. Republished: Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis. *Drug and Therapeutics Bulletin*. 2020 Apr 1;58(4):60-3.
19. Anderson S, Cotiguala L, Tischer S, Park JM, McMurry K. Review of newer antidiabetic agents for diabetes management in kidney transplant recipients. *Annals of Pharmacotherapy*. 2021 Apr;55(4):496-508.
20. Vallianou NG, Tsilingiris D, Kounatidis D, Lempesis IG, Karampela I, Dalamaga M. Sodiumglucose cotransporter2 inhibitors in obesity and associated cardiometabolic disorders: where do we stand. *Pol Arch Intern Med*. 2022 Oct 21;132(10):16342.
21. Reddi AS. Chronic kidney disease. In *Absolute Nephrology Review: An Essential Q & A Study Guide* 2022 Jan 27 (pp. 211-270). Cham: Springer International Publishing.



22. Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus. *Current medicinal chemistry*. 2023 Aug 1;30(25):2850-63.
23. Ortiz A, Alcázar Arroyo R, Casado Escribano PP, Fernández-Fernández B, Martínez Debén F, Mediavilla JD, Michan-Doña A, Soler MJ, Gorriz JL. Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone. *Expert Review of Clinical Pharmacology*. 2023 Jun 3;16(6):519-31.
24. Kolkhof P, Joseph A, Kintscher U. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders– New perspectives for combination therapy. *Pharmacological Research*. 2021 Oct 1;172:105859.
25. Bilen Y, Almoushref A, Alkwatli K, Osman O, Mehdi A, Sawaf H. Treatment and practical considerations of diabetic kidney disease. *Frontiers in Medicine*. 2023 Dec 1;10:1264497.